Novel regulators of phosphate homeostasis and bone metabolism

Therapeutic Apheresis and Dialysis

Volumn 11, Issue SUPPL. 1, 2007, Pages

  Jüppner, Harald ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Bone metabolism; Dentin matrix protein; Fibroblast growth factor 23; NaPi IIa; NaPi IIc; Phosphate homeostasis

Indexed keywords

CALCITRIOL; CREATININE; FIBROBLAST GROWTH FACTOR 23; MESSENGER RNA; PHOSPHATE; POLYPEPTIDE N ACETYLGALACTOSAMINYLTRANSFERASE 3; TRANSFERASE; UNCLASSIFIED DRUG; URIDINE DIPHOSPHATE N ACETYLGALACTOSAMINE; URIDINE DIPHOSPHATE N ALPHA DEXTRO ACETYLGALACTOSAMINE;

AUTOSOMAL DOMINANT INHERITANCE; BONE METABOLISM; CHRONIC KIDNEY DISEASE; CONFERENCE PAPER; CREATININE BLOOD LEVEL; GENE MUTATION; HOMOZYGOSITY; HUMAN; HYPOPHOSPHATEMIA; NEPHROLITHIASIS; NONHUMAN; OSTEOMALACIA; OSTEOPOROSIS; OSTEOSCLEROSIS; PHOSPHATE METABOLISM; PHOSPHATURIA; PRIORITY JOURNAL; VITAMIN D RESISTANT RICKETS; WASTING SYNDROME;

ANIMALS; BONE AND BONES; FEMALE; FIBROBLAST GROWTH FACTORS; HOMEOSTASIS; HUMANS; MALE; PHOSPHATES; PHOSPHORUS METABOLISM DISORDERS; SIGNAL TRANSDUCTION;

EID: 35948943974     PISSN: 17449979     EISSN: 17449987     Source Type: Journal    
DOI: 10.1111/j.1744-9987.2007.00513.x     Document Type: Conference Paper

References (54)

1. Potts JT Bringhurst FR, Gardella TJ et al. Parathyroid hormone: physiology, chemistry, biosynthesis, secretion, metabolism, and mode of action. In: DeGroot LJ, ed. Endocrinology. Philadelphia, PA: W.B. Saunders, 1996 920 65.
2. Jüppner H, Gardella T, Brown E et al. Parathyroid hormone and parathyroid hormone-related peptide in the regulation of calcium homeostasis and bone development. In: DeGroot L, Jameson J, eds. Endocrinology, 5th edn. Philadelphia, PA: W.B. Saunders Company, 2005 1377 417.
3. Segawa H, Yamanaka S, Onitsuka A et al. Parathyroid hormone-dependent endocytosis of renal type IIc Na-Pi cotransporter. Am J Physiol Renal Physiol 2007 292: F395 403.
4. Mensenkamp A, Hoenderop J, Bindels R. TRPV5, the gateway to Ca2+ homeostasis. Handb Exp Pharmacol 2007 179: 207 20.
5. Potts JT Jüppner H. Parathyroid Hormone and parathyroid hormone-related peptide in calcium homeostasis, bone metabolism, and bone development: the proteins, their genes, and receptors. In: Avioli L, Krane S, eds. Metabolic Bone Disease. New York: Academic Press, 1997 51 94.
6. The HYP Consortium. A gene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets. Nat Genet 1995 11: 130 6.
7. The ADHR Consortium; White KE, Evans WE et al. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF-23. Nat Genet 2000 26: 345 8.
8. Bergwitz C, Banerjee S, Abu-Zahra H, Miyauchi A, Jüppner H. A homozygous missense mutation S129P in FGF-23 causes tumoral calcinosis with hyperphosphatemia. J Bone Miner Res 2005 20: F444.
9. Lorenz-Depiereux B, Benet-Pages A, Eckstein G et al. Hereditary hypophosphatemic rickets with hypercalciuria is caused by mutations in the sodium/phosphate cotransporter gene SLC34A3. Am J Hum Genet 2006 78: 193 201.
10. Lorenz-Depiereux B, Bastepe M, Benet-Pagès A et al. 2006 DMP1 mutations in autosomal recessive hypophosphatemia implicate a bone matrix protein in the regulation of phosphate homeostasis. Nat Genet 2006 38: 1248 50.
11. Topaz O, Shurman D, Bergman R et al. Mutations in GALNT3, encoding a protein involved in O-linked glycosylation, cause familial tumoral calcinosis. Nat Genet 2004 36: 579 81.
12. Prié D, Huart V, Bakouh N et al. Nephrolithiasis and osteoporosis associated with hypophosphatemia caused by mutations in the type 2a sodium-phosphate cotransporter. N Engl J Med 2002 347: 983 91.
13. Bergwitz C, Roslin N, Tieder M et al. SLC34A3 mutations in patients with hereditary hypophosphatemic rickets with hypercalciuria (HHRH) predict a key role for the sodium-phosphate co-transporter NaPi-IIc in maintaining phosphate homeostasis and skeletal function. Am J Hum Genet 2006 78: 179 92.
14. Ichikawa S, Imel EA, Kreiter ML et al. Homozygous missense mutation in human KLOTHO causes severe tumoral calcinosis. J Clin Invest 2007 117: 2684 91
15. Kurosu H, Ogawa Y, Miyoshi M et al. 2006 Regulation of fibroblast growth factor-23 signaling by Klotho. J Biol Chem 2007 281: 6120 3.
16. Urakawa I, Yamazaki Y, Shimada T et al. Klotho converts canonical FGF receptor into a specific receptor for FGF-23. Nature 2006 444: 770 4.
17. Feng JQ, Ward LM, Liu S et al. Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. Nat Genet 2006 38: 1310 15.
18. Rowe P, Kumagai Y, Gutierrez G et al. MEPE has the properties of an osteoblastic phosphatonin and minhibin. Bone 2004 34: 303 19.
19. Carpenter T, Ellis B, Insogna K, Philbrick W, Sterpka J, Shimkets R. Fibroblast growth factor 7: an inhibitor of phosphate transport derived from oncogenic osteomalacia-causing tumors. J Clin Endocrinol Metab 2005 90: 1012 20.
20. Berndt T, Bielesz B, Craig T et al. Secreted frizzled-related protein-4 reduces sodium-phosphate co-transporter abundance and activity in proximal tubule cells. Pflugers Arch 2006 451: 579 87.
21. Berndt T, Craig T, Bowe A et al. Secreted frizzled-related protein 4 is a potent tumor-derived phosphaturic agent. J Clin Invest 2003 112: 785 94.
22. Tieder M, Modai D, Samuel R et al. Hereditary hypophosphatemic rickets with hypercalciuria. N Engl J Med 1985 312: 611 17.
23. Tieder M, Modai D, Shaked U et al. "Idiopathic" hypercalciuria and hereditary hypophosphatemic rickets. Two phenotypical expressions of a common genetic defect. N Engl J Med 1987 316: 125 9.
24. Segawa H, Kaneko I, Takahashi A et al. Growth-related renal type II Na/Pi cotransporter. J Biol Chem 2002 277: 19665 72.
25. Ichikawa S, Sorenson AH, Imel EA, Friedman NE, Gertner JM, Econs MJ. Intronic deletions in the SLC34A3 gene cause hereditary hypophosphatemic rickets with hypercalciuria. J Clin Endocrinol Metab 2006 91: 4022 7.
26. Kremke B, Bergwitz C, Ahrens W et al. Hypophosphatemic rickets with hyper calciuria due to mutation in SLC34A3/NaPi-llc can be masked by vitamin D deficiency and can be associated with renal calcifications. Eur J Endocrinol (in press).
27. Virkki L, Forster I, Hernando N, Biber J, Murer H. Functional characterization of two naturally occurring mutations in the human sodium-phosphate cotransporter type IIa. J Bone Miner Res 2003 18: 2135 41.
28. Econs M, McEnery P. Autosomal dominant hypophosphatemic rickets/osteomalacia: clinical characterization of a novel renal phosphate-wasting disorder. J Clin Endocrinol Metab 1997 82: 674 81.
29. Econs M, McEnery P, Lennon F, Speer M. Autosomal dominant hypophosphatemic rickets is linked to chromosome 12p13. J Clin Invest 1997 100: 2653 7.
30. White K, Carn G, Lorenz-Depiereux B, Benet-Pages A, Strom T, Econs M. Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23. Kidney Int 2001 60: 2079 86.
31. White K, Larsson T, Econs M. The roles of specific genes implicated as circulating factors involved in normal and disordered phosphate homeostasis: Frp-4, MEPE, and FGF-23. Endocr Rev 2006 27: 221 41.
32. Shimada T, Mizutani S, Muto T et al. 2001 Cloning and characterization of FGF-23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci USA 2001 98: 6500 5.
33. White K, Jonsson K, Carn G et al. The autosomal dominant hypophosphatemic rickets (ADHR) gene is a secreted polypeptide overexpressed by tumors that cause phosphate wasting. J Clin Endocrinol Metab 2001 86: 497 500.
34. Yamazaki Y, Okazaki R, Shibata M et al. Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. J Clin Endocrinol Metab 2002 87: 4957 60.
35. Jonsson K, Zahradnik R, Larsson T et al. Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med 2003 348: 1656 62.
36. Imel E, Peacock M, Pitukcheewanont P et al. Sensitivity of Fibroblast Growth Factor 23 measurements in tumor-induced osteomalacia. J Clin Endocrinol Metab 2006 91: 2055 61.
37. Larsson T, Nisbeth U, Ljunggren O, Jüppner H, Jonsson K. Circulating concentration of FGF-23 increases as renalfunction declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int 2003 64: 2272 9.
38. Imanishi Y, Inaba M, Nakatsuka K et al. FGF-23 in patients with end-stage renal disease on hemodialysis. Kidney Int 2004 65: 1943 6.
39. Gutierrez O, Isakova T, Rhee E et al. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease: new insight into secondary hyperparathyroidism. J Am Soc Nephrol 2005 16: 2205 15.
40. Nagano N, Miyata S, Abe M, Kobayashi N, Wakita S, Yamashita T, Wada M. Effect of manipulating serum phosphorus with phosphate binder on circulating PTH and FGF-23 in renal failure rats. Kidney Int 2006 69: 531 7.
41. Wesseling K, Jüppner H, Jimenez W et al. Regulation of bone remodeling and mineralization by FGF-23 and PTH. J Am Soc Nephrol 2006 17: TH-F CO88 (abstract).
42. Weber T, Liu S, Indridason O, Quarles L Serum FGF-23 levels in normal and disordered phosphorus homeostasis. J Bone Miner Res 2003 18: 1227 34.
43. Liu S, Brown T, Zhou J et al. Role of matrix extracellular phosphoglycoprotein in the pathogenesis of X-linked hypophosphatemia. J Am Soc Nephrol 2005 16: 1645 53.
44. Sitara D, Razzaque MS, Hesse M et al. Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice. Matrix Biol 2004 23: 421 32.
45. Liu S, Zhou J, Tang W, Jiang X, Rowe DW, Quarles LD. Pathogenic role of FGF-23 in Hyp mice. Am J Physiol Endocrinol Metab 2006 291: E38 49.
46. Burnett S, Gunawardene S, Bringhurst F, Jüppner H, Lee H, Finkelstein J. Regulation of C-terminal and intact FGF-23 by dietary phosphate in men and women. J Bone Miner Res 2006 21: 1187 96.
47. Perwad F, Azam N, Zhang M, Yamashita T, Tenenhouse H, Portale A. Dietary and serum phosphorus regulate fibroblast growth factor 23 expression and 1,25-dihydroxyvitamin D metabolism in mice. Endocrinology 2005 146: 5358 64.
48. Kolek O, Hines E, Jones M et al. 1alpha,25-Dihydroxyvitamin D3 upregulates FGF-23 gene expression in bone: the final link in a renal-gastrointestinal-skeletal axis that controls phosphate transport. Am J Physiol Gastrointest Liver Physiol 2005 289: G1036 42.
49. White KE, Cabral JM, Davis SI et al. Mutations that cause osteoglophonic dysplasia define novel roles for FGFR1 in bone elongation. Am J Hum Genet 2005 76: 361 7.
50. Farrow E, Davis S, Mooney S et al. Extended mutational analyses of FGFR1 in osteoglophonic dysplasia. Am J Med Genet 2006 140: 537 9.
51. Bastepe M, Shlossberg H, Murdock H, Jüppner H, Rittmaster R. A Lebanese Family with Osteosclerosis and Hypophosphatemia. J Bone Miner Res 1999 14: S558.
52. Ye L, Mishina Y, Chen D et al. Dmp1-deficient mice display severe defects in cartilage formation responsible for a chondrodysplasia-like phenotype. J Biol Chem 2005 280: 6197 203.
53. Harris S, Gluhak-Heinrich J, Harris M et al. MEPE is overexpressed in osteocytes of the DMP1 (Dentin Matrix Protein 1) null mouse, contributing to the hypophosphatemia and osteomalacia. J Bone Miner Res 2005 20: SA462.
54. Ling Y, Rios HF, Myers ER, Lu Y, Feng JQ, Boskey AL. DMP1 depletion decreases bone mineralization in vivo: an FTIR imaging analysis. J Bone Miner Res 2005 Dec 20(12): 2169 77. Epub 2005.